drugset / Trial / NCT02724566
Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers
RandomizedCrossoverDouble-blindBasic science
Summary
Preclinical studies have demonstrated in mouse models that (PYR1)-apelin-13 exerts a glucose-regulating action in vivo. The (PYR1)-apelin-13 effect on insulin sensitivity in healthy overweighed volunteers has been previously assessed in a phase I clinical trial (APELINS study; NCT02033473). The APELINS-2 clinical trial aims to expand the initial proof of concept to the population targeted by future innovative insulin-sensitizing therapies: patients living with type 2 diabetes.
Timeline
- Start
- 2016-05
- Primary completion
- 2017-04
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apelin | Peptide | 30 unknown | Intravenous |